Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer. - Wikidata - awgldk - TriplyDB

Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer.

Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer.

http://www.wikidata.org/entity/Q37362623

about

Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer.Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors.Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells.PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma.Cancer-induced heterogeneous immunosuppressive tumor microenvironments and their personalized modulation.Next generation predictive biomarkers for immune checkpoint inhibition.A systematic and genome-wide correlation meta-analysis of PD-L1 expression and targetable NSCLC driver genes.PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis.Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden.Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors.TUSC2 downregulates PD-L1 expression in non-small cell lung cancer (NSCLC).PD-L1 is a Prognostic Biomarker in Resected NSCLC Patients with Moderate/high Smoking History and Elevated Serum SCCA Level.CD274 (PDL1) and JAK2 genomic amplifications in pulmonary squamous-cell and adenocarcinoma patients.PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics.Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system.Association between PD-L1 expression and driver gene status in non-small-cell lung cancer: a meta-analysis.Impact of heavy smoking on the benefits from first-line EGFR-TKI therapy in patients with advanced lung adenocarcinoma.Towards a better cancer precision medicine: systems biology meets immunotherapy.Construction of an anti-programmed death-ligand 1 chimeric antigen receptor and determination of its antitumor function with transduced cells.Prognostic significance of immune cells in non-small cell lung cancer: meta-analysis.Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers.Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors

P2860

Q37702792-1071284B-9DAA-4C57-A703-46A3AA4135D8 Q38730989-B48A9CAF-3A30-48CF-8D70-1E90E46D3C84 Q38746756-D48495F6-D0FD-489A-BA42-791C4C87BE15 Q38839136-04FCC498-1960-4320-B884-640A83F25CE7 Q38892904-71435EA4-C62A-4A44-BCF3-0A4427C06223 Q39016247-A958E970-1D85-4ED3-B11B-69BEFB6D48C8 Q41306256-8E02F7E7-5F94-41C7-9E39-E556B2A6E287 Q41579669-17302DA0-E156-4A02-993A-12AEA6E5C0D3 Q41706974-F7F4A928-B18A-41E8-B5D3-BCF236D96E74 Q42700740-7817A738-8DD7-4DAB-9A9C-E5065E59768D Q47127243-DCA60862-8FA6-4E4C-93C0-FC614DF5A590 Q47135594-59D04D63-7AF5-4FA7-AE56-A30FD636C427 Q48262038-D8C51820-116A-4302-BC77-4029E06E77D1 Q49494082-779C7A19-6A1F-4E2E-A4E6-BB0FDC1051A7 Q50070316-2DE21157-8D09-417D-B892-DE2E01CD703A Q52684139-8DCF87E4-3261-48D1-9EB7-BA2F22237EE4 Q54123954-B32320ED-6D39-4584-951D-A478F215A11D Q54967177-EF75F8C5-748F-4A94-A434-4AC6E7BE7EA0 Q55381164-58AE88AE-F4F6-4364-8616-F43728803C65 Q55440274-DB3DDD68-54F2-43DF-B769-415DC120E2B0 Q55518010-1EBF09A2-701F-4C98-93F9-E69D50F7316E Q56890243-CCA66330-1CD0-4753-8E42-37417D92E791

P2860

Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer.

http://www.wikidata.org/entity/Q37362623

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on April 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer.

@en

Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer.

@nl

type

label

Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer.

@en

Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer.

@nl

prefLabel

Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer.

@en

Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer.

@nl

P1433

Q37362623-F0988030-0945-4475-99ED-2E59FB9B9D9C

P1476

Q37362623-F9496A06-61F0-4D7F-8E7B-51B828BD8CA9

P2093

Q37362623-085D045C-87F1-4F0F-9E48-529E6F1A2279

Q37362623-2A34A42B-20B0-46F1-AB75-7FB571392FC7

Q37362623-4CACD54A-EEB8-4B8D-A3E7-9D72FF3005BA

Q37362623-74A76865-6D94-4BF1-A255-BA32F2646BC0

Q37362623-750C7AE8-7BEE-4299-B000-3B8501B8CF92

Q37362623-AEFEA0B1-CC51-499B-9208-348101FB919B

Q37362623-B168EF09-C4FA-48EE-B0BD-C5267950FE11

Q37362623-B598F818-3BCD-4CA8-80B6-E4A91FB2255A

Q37362623-C718A457-9186-4D4D-9B5F-3C051B8D770D

Q37362623-D3B30102-1BEA-4A95-A1A5-223227F4AD07

P2860

Q37362623-0443A6BA-885B-40E6-8BFA-F179CE6C01FC

Q37362623-226F9566-81FB-422D-8261-9D5872DE03FE

Q37362623-280E3B69-8D23-4D4D-9862-9AD8ED441FC6

Q37362623-2A98D271-B91D-4065-AB53-068C58252755

Q37362623-3993B1E9-0391-4ED8-91BA-58C01F518EC4

Q37362623-3D15A350-D63B-4988-9104-A2533CD6D924

Q37362623-3EC7F12A-2E5E-45EE-94E6-BA6E31345048

Q37362623-41EA3292-FE60-4E51-A88E-5595DE48CE81

Q37362623-4B7EF0B0-AA28-4EEA-A5B0-006AE83BC16E

Q37362623-4BE0984E-494A-4B18-B1D3-FCF05F4BE459

P304

Q37362623-7E26DD5E-4DE5-4CF4-B205-94EC5F38ED73

P31

Q37362623-B1624DD8-DD0F-400A-B80D-3CDA9F75A9E0

P356

Q37362623-55D587DE-304E-40A0-80B6-161320726817

P407

Q37362623-136A3F7F-284A-45B9-B22C-89ED6DB3EC9E

P433

Q37362623-5276EA8B-3355-4B1B-AD71-B0E88769E52C

P478

Q37362623-2D43233B-D797-4CF2-8361-48830DC404AB

P50

Q37362623-2CF72980-430B-41D0-A937-ED2474D96BC4

Q37362623-CF9CCD42-EDFD-41E2-ADBB-365375455F21

P577

Q37362623-E5E5451C-B83D-4EB2-A92F-FAE430FCDC7B

P698

Q37362623-DC24DF92-DFFD-472C-A5F5-37B586D2237C

P932

Q37362623-80D3A2EC-0FB1-4788-A3CF-213904E4361B

P356

ONCOTARGET.8528

P1433

P1476

Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer.

@en

P2093

Akikazu Kawase

http://www.w3.org/2001/XMLSchema#string

Haruhiko Sugimura

http://www.w3.org/2001/XMLSchema#string

Hiroki Mori

http://www.w3.org/2001/XMLSchema#string

Hiroshi Niwa

http://www.w3.org/2001/XMLSchema#string

Hiroshi Ogawa

http://www.w3.org/2001/XMLSchema#string

Kazuhito Funai

http://www.w3.org/2001/XMLSchema#string

Kazutaka Mori

http://www.w3.org/2001/XMLSchema#string

Masayuki Tanahashi

http://www.w3.org/2001/XMLSchema#string

Naoki Inui

http://www.w3.org/2001/XMLSchema#string

Nobuya Kurabe

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanisms of change in gene copy number

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma

New immunotherapies targeting the PD-1 pathway

Global cancer statistics, 2012

The blockade of immune checkpoints in cancer immunotherapy

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

Comprehensive molecular characterization of gastric adenocarcinoma

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

P304

32113-32128

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.8528

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Kazuya Shinmura

Katsuhiro Yoshimura

P577

2016-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27050074

http://www.w3.org/2001/XMLSchema#string

P932

5078001

http://www.w3.org/2001/XMLSchema#string